Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Vectus Taps Pulmonary Fibrosis Expert as VB0004 Trial Plans Advance

VBS: $0.076 +8.57% · MC: $4M

Vectus Biosystems has appointed Professor Tamera Corte, a pulmonary fibrosis specialist and experienced clinical-trial investigator, as Chief Clinical Advisor to guide development of its lead candidate VB0004. The appointment supports preparations for a planned adaptive Phase Ib/IIa trial in idiopathic pulmonary fibrosis; FDA written feedback on the proposed programme is expected by mid-November and is intended to inform the next clinical and regulatory steps.

Source announcements: 2026-11-09 11:47 to 2026-11-09 11:47 Sydney time
Story updated 2026-11-09 11:50 Sydney time
SourcesAppointment of Prof Tamera Corte as Chief Clinical Advisor
Comments